Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation

Abstract

Study M05-730 was conducted to compare the safety, tolerability, pharmacokinetics (PK) and antiviral activity for once-daily (QD) and twice-daily (BID) lopinavir/ritonavir (LPV/r) tablet in antiretroviral-naïve subjects. The LPV/ r QD regimen was shown to be non-inferior to the BID regimen. This analysis explores the population PK and pharmacodynamics (PD) of the LPV/r tablets in HIVinfected subjects.